Aclidinium Bromide holds promising inhibitory effects in A549 lung cancer cells potentials by regulating PI3K / AKT signaling pathway.

CONCLUSION: Our results reveals that Aclidinium Bromide behaves as a novel M3R antagonist, and may inhibit lung cancer cell growth by regulating the PI3K/AKT signaling pathway, which sheds some light on that it might be a potential therapeutic agent for lung cancer. PMID: 31128006 [PubMed - in process]
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research